Clinical trials: Philadelphia Chromosome Negative ALL, active
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
- Trial name
- NCT07333183
- Testing
- inhaled mosliciguat, Dry Powder Inhaler
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pulmovant, Inc.
Acute Lymphoblastic Leukemia
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual…
- Trial name
- NCT04179929
- Testing
- Pediatric-type of chemotherapy, allogeneic HSCT
- Where
- 108 sites in Spain
- Volunteers
- 300 people
- Sponsor
- PETHEMA Foundation
Gastroesophageal Reflux Disease (GERD), Gastroesophageal Reflux (GER)
Development of Machine Learning Models to Predict Postoperative GERD Symptom Resolution After Laparoscopic Nissen Fundoplication
This study aims to develop machine learning models to predict postoperative gastroesophageal reflux symptom resolution after laparoscopic Nissen fundoplication using Elastic Net regression and synthetic minority oversampling…
- Trial name
- NCT06862037
- Testing
- Laparoscopic Nissen fundoplication
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Korea University Anam Hospital
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
The current Standard of Care (SoC) in younger patients with Ph+ ALL is Imatinib in combination with low-dose chemotherapy, change of TKI in case of persistent MRD above 10-3 after consolidation I and indication for stem cell…
- Trial name
- GMALL-EVOLVE (NCT06061094)
- Testing
- Imatinib, Ponatinib, Blinatumomab
- Where
- 85 sites in Germany
- Volunteers
- 220 people
- Sponsor
- Goethe University
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Rutgers University Study of the Genetics of Pulmonary Hypertension
The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligible, and a diagnosis of PH is NOT required.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- RUGCC-PH (NCT07217522)
- Testing
- Saliva sample, Health surveys
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Non-Muscle Invasive Bladder Neoplasms
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin…
- Trial name
- SunRISe-5 (NCT06211764)
- Testing
- TAR-200, Mitomycin C, Gemcitabine
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 272 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension (PAH)
imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge.
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension
- Trial name
- OPENLINE (NCT06850792)
- Testing
- Telemedicine-Based Adherence Support
- Where
- Brazil
- Volunteers
- 61 people
- Sponsor
- University of Sao Paulo General Hospital
Type 1 Diabetes (T1D)
Feasibility Study of a Continuous Glucose-Ketone Monitoring Device in People With Type 1 Diabetes
The goal of this study is to evaluate a CGM-CKM device during insulin suspension in patients with type 1 diabetes. 10 patients with T1D will be recruited for a pilot study. The patients will visit CTRU at Stanford Medical School.
- Trial name
- NCT06977633
- Testing
- Temporary Insulin Suspension, Glucose and ketone sensor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mahla Poudineh
ALL
A Multicenter Study of CAR-T Cells in Primary Ph+All
A Multicenter Study of CD19 CAR-T Cells in the Treatment of Adult Patients With Primary Ph Chromosome Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT07252336
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Chronic Thromboembolic Disease
BPA in CTEPD Without PH
The goal of this clinical trial is to assess the effect of Balloon Pulmonary Angioplasty (BPA) on quality of life and exercise capacity in patients with chronic tromboembolic pulmonary disease (CTEPD) without pulmonary…
- Trial name
- BALLOON (NCT06090838)
- Testing
- Balloon Pulmonary Angioplasty (BPA)
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Amsterdam UMC, location VUmc
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
This phase II trial studies how well low-intensity chemotherapy and ponatinib work in treating patients with Philadelphia chromosome-positive and/or BCR-ABL positive acute lymphoblastic leukemia that may have come back or is not…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03147612
- Testing
- Blinatumomab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Uterine Sarcoma, Uterine Leiomyosarcoma
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas.
- Conditions
- Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma, ESS
- Trial name
- NCT07467772
- Testing
- Elacestrant
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined…
- Trial name
- NCT06051409
- Testing
- Olverembatinib, Investigator's choice of TKI
- Where
- 90 sites in United States, Australia and 10 more
- Volunteers
- 350 people
- Sponsor
- Ascentage Pharma Group Inc.
Pulmonary Hypertension Due to Left Heart Disease, Heart Failure With Preserved Ejection Fraction
Training in HFpEF-PH
Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved…
- Trial name
- TRAIN HFpEF (NCT05464238)
- Testing
- Exercise rehabilitation, Standard treatment
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 90 people
- Sponsor
- Heidelberg University
Combining Ultrasound Assessment of Sealing Quality With Chemical Monitoring , May Provide Valuable Insights to Compare Effectiveness of Different SAD
The Use of Ultrasound to Assess the Airway Anatomy Regarding Pharyngeal Seal and Its Protective Role Throw a Chemical Test for Three Supraglottic Devices (ProSeal LMA, I-gel, and I-gel Plus)
The goal of this clinical trial is to to evaluate the sealing quality of three second-generation SADs (ProSeal LMA, i-gel, and i-gel Plus) using ultrasonography to measure the cross-sectional area (CSA) of sealing…
- Trial name
- LMA (NCT07642115)
- Testing
- evaluate the sealing quality (ProSeal LMA)using ultrasonography and a biochemical non invasive test to evaluate regurgitation, evaluate the sealing quality of SGA device ( i-gel)using ultrasonography and a biochemical test for assessment of regurgitation, evaluate the sealing quality of SGA device ( i-gel plus )using ultrasonography and a biochemical test for assessment of regurgitation
- Where
- Egypt
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Phase II Clinical Trial, Blinatumomab
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
- Conditions
- Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia
- Trial name
- NCT07178912
- Testing
- Blinatumomab, olverembatinib
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT01424982
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia, Chronic Phase
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
This is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque Die(QD).
- Trial name
- NCT03722420
- Testing
- Radotinib, Imatinib
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
The goal of this clinical trial is to learn if Asciminib, a first in class allosteric inhibitor, as a add-on maintenance therapy can provides benefits and further prevents relapse in post allogenic hematopoietic stem-cell…
- Conditions
- Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL), Haematopoietic Stem Cell Transplant, Allogeneic
- Trial name
- ASIM-POST Ph+ (NCT07493408)
- Testing
- Asciminib add-on, Imatinib, Dasatinib
- Where
- Hong Kong
- Volunteers
- 45 people
- Sponsor
- The University of Hong Kong
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib.
- Trial name
- NCT03589326
- Testing
- Ponatinib, Imatinib, Vincristine
- Where
- 92 sites in United States, Argentina and 18 more
- Volunteers
- 245 people
- Sponsor
- Takeda